Literature DB >> 9479081

Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy.

J J DiGiovanna1, N Patronas, D Katz, D Abangan, K H Kraemer.   

Abstract

BACKGROUND: Patients with xeroderma pigmentosum (XP) frequently develop sunlight-induced skin cancer. Infrequently, internal neoplasms may also occur. A 21-year-old patient with XP, who had many skin cancers, developed a rare internal tumour - a grade II diffuse fibrillary spinal cord astrocytoma - during a break in a therapeutic trial of isotretinoin for skin cancer prevention. Treatment of neoplasms in XP patients presents special difficulties because of their defect in DNA repair.
OBJECTIVE: The study objective was to raise awareness of the cancer surveillance process in XP patients and the concerns involved in choice of therapy.
METHODS: Since the spinal cord tumour was inoperable, the patient was treated with x-radiation, continued on isotretinoin treatment and was followed closely for tumour response.
RESULTS: Despite sensitivity to sunlight, the patient had a normal acute response to the x-ray treatment without excessive skin reaction. Serial examinations by magnetic resonance imaging (MRI) starting 8 months after x-ray treatment was initiated, showed a marked gadolinium enhancement followed by regression. This clearing was first seen at 2 years after biopsy and persisted to at least 9 years after treatment.
CONCLUSION: In contrast to the exaggerated sensitivity to UV radiation, XP patients may tolerate therapeutic doses of x-radiation. Isotretinoin treatment may have contributed to the good response of this spinal cord astrocytoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479081     DOI: 10.1177/120347549800200308

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  19 in total

Review 1.  [Hereditary photodermatoses].

Authors:  P Poblete-Gutiérrez; W H C Burgdorf; C Has; M Berneburg; J Frank
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

2.  Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.

Authors:  Porcia T Bradford; Alisa M Goldstein; Deborah Tamura; Sikandar G Khan; Takahiro Ueda; Jennifer Boyle; Kyu-Seon Oh; Kyoko Imoto; Hiroki Inui; Shin-Ichi Moriwaki; Steffen Emmert; Kristen M Pike; Arati Raziuddin; Teri M Plona; John J DiGiovanna; Margaret A Tucker; Kenneth H Kraemer
Journal:  J Med Genet       Date:  2010-11-19       Impact factor: 6.318

Review 3.  Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature.

Authors:  Hema L Ramkumar; Brian P Brooks; Xiaoguang Cao; Deborah Tamura; John J Digiovanna; Kenneth H Kraemer; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 6.048

4.  Predisposition to hematologic malignancies in patients with xeroderma pigmentosum.

Authors:  Karolyn A Oetjen; Melissa A Levoska; Deborah Tamura; Sawa Ito; Dorothea Douglas; Sikandar G Khan; Katherine R Calvo; Kenneth H Kraemer; John J DiGiovanna
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

Review 5.  Oxidative and energy metabolism as potential clues for clinical heterogeneity in nucleotide excision repair disorders.

Authors:  Mohsen Hosseini; Khaled Ezzedine; Alain Taieb; Hamid R Rezvani
Journal:  J Invest Dermatol       Date:  2014-10-09       Impact factor: 8.551

6.  Re-irradiation of metastatic disease in the neck from xeroderma pigmentosum.

Authors:  C C Wei; N J Sanfilippo; D Myssiorek
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

Review 7.  Therapeutics of xeroderma pigmentosum: A PRISMA-compliant systematic review.

Authors:  Fernando Antônio Gomes de Andrade; Claudio Eduardo de Oliveira Cavalcanti; Felipe Contoli Isoldi; Lydia Masako Ferreira
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

Review 8.  Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.

Authors:  Michael F Walsh; Vivian Y Chang; Wendy K Kohlmann; Hamish S Scott; Christopher Cunniff; Franck Bourdeaut; Jan J Molenaar; Christopher C Porter; John T Sandlund; Sharon E Plon; Lisa L Wang; Sharon A Savage
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

Review 9.  Shining a light on xeroderma pigmentosum.

Authors:  John J DiGiovanna; Kenneth H Kraemer
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

10.  Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect.

Authors:  Hiva Fassihi; Mieran Sethi; Heather Fawcett; Jonathan Wing; Natalie Chandler; Shehla Mohammed; Emma Craythorne; Ana M S Morley; Rongxuan Lim; Sally Turner; Tanya Henshaw; Isabel Garrood; Paola Giunti; Tammy Hedderly; Adesoji Abiona; Harsha Naik; Gemma Harrop; David McGibbon; Nicolaas G J Jaspers; Elena Botta; Tiziana Nardo; Miria Stefanini; Antony R Young; Robert P E Sarkany; Alan R Lehmann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.